NanoCelle® Fexodenadine

Product description

NanoCelle® Fexofenadine (as hydrochloride) is an oral-active non-sedating histamine H1-receptor antagonist.

IP RIGHTS:Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: CanadaApplication number: 2978179Filing Date: 2nd March 16 Status: Filed

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: EuropeApplication number: 16759418.3Filing Date: 2nd March 16 Status: Under examination

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: New ZealandApplication number: 735138Filing Date: 2nd March 2016 Status: Examination Requested

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: SingaporeApplication number: 11201707068XFiling Date: 2nd March 2016 Status: Under examination

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: United StatesApplication number: 15/555038 Filing Date: 2nd March 2016Status: Under examination

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: Hong KongApplication number: 18103321.4Filing Date: 2nd March 2016Status: Filed

Specifications

Categories	Pharmaceutical Machinery & TechnologyBioavailability enhancement; Finished Dosage Forms
Sales markets	Western Europe; Eastern Europe; Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Central/South America
Supplied from	Australia

More products from Medlab Clinical LTD

NanoCBD

NanoCBD is a formulation containing 16.67 mg/mL cannabidiol (CBD) as active ingredient, in a sub-micron spray applied to the oro-buccal membrane. The CBD is sourced from cannabis (hemp) strains and extracted from plant parts that produce high levels of CBD, but no THC.

IP RIGHTS:
Patent T...

More info

MultiBiotic™

MultiBiotic™ is an evidence-based multi-species probiotic specifically designed to target end-organ function and support gastrointestinal health and maintenance. MultiBiotic™ is an ARTG listed medicine and available in Pharmacies and HCP's in AU, NZ, SG and HK. Presently MultiBiotic™ is in Phase 1 c...

More info

NanaBidial™

NanaBidial™ is an investigative new product containing 20 mg/mL of Cannabidiol (CBD) and and <1mg/mL of delta-9-tetrahydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.
CLINICAL TRIAL:
The buccal administration of a NanoCelle™ CBD preparation to healthy volunteers: a ...

More info

NanoStat™

NanoStat™ is Medlab's patented NanoCelle® delivery platform (buccal spray) for the treatment of elevated cholesterol. Atorvastatin (as calcium) belongs to the class of medicines known as “statins”, more specifically called HMG-CoA reductase inhibitors. HMG-CoA reductase is an enzyme involved in regulating cho...

More info

NanoTest™

NanoCelle® delivery platform (buccal spray) for increasing low testosterone levels in men.
IP RIGHTS:
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted

Patent Title: Tra...

More info

NanUlin™

NanoCelle® delivery platform (buccal spray) for type 2 diabetics.
IP RIGHTS:
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted

Patent Title: Transmucosal and transdermal...

More info

View all our products (10)